Barclays PLC Castle Biosciences Inc Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Barclays PLC holds 47,425 shares of CSTL stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,425
Previous 39,380
20.43%
Holding current value
$1.03 Million
Previous $850,000
23.53%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CSTL
# of Institutions
162Shares Held
25.3MCall Options Held
82.2KPut Options Held
150K-
Black Rock Inc. New York, NY2.6MShares$56.5 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.55MShares$55.5 Million0.3% of portfolio
-
Granahan Investment Management, LLC Waltham, MA1.63MShares$35.4 Million1.3% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.53MShares$33.4 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.49MShares$32.5 Million0.0% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $572M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...